Pro-active Genetic Testing in Kidney Transplant Patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05298904

Enrollment

177

Registered

2022-03-28

Start date

2022-03-28

Completion date

2038-03-01

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Transplant

Brief summary

The purpose of this study is to determine the prevalence of genetic mutations that increase the risk of cancer and other medically actionable diseases in kidney transplant patients and to assess the impact of genetic testing on subsequent surveillance for cancer.

Interventions

DIAGNOSTIC_TESTGenetic Health Screen Panel

This panel covers cardiomyopathy genes, and cancer genes. The results of this panel are reported as Positive (pathogenic or likely pathogenic mutation identified in one or more genes) or Negative (no pathogenic/likely pathogenic mutations identified).

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

\- Post transplant Kidney and Kidney Pancreas recipients.

Exclusion criteria

* Simultaneous Liver Kidney Transplant. * Simultaneous Heart Kidney Transplant. * Non renal transplant history.

Design outcomes

Primary

Measure	Time frame	Description
Genetic mutations of cancer	1 year	Number of subjects to have genetic mutations of cancer in kidney transplant patients receiving care at Mayo Clinic Arizona

Secondary

Measure	Time frame	Description
The impact of genetic testing	1 year	Current guidelines for cancer screening have limitations, as its mostly age based. Immunosuppression can lead to a increased risk of cancer in the kidney transplant population. By utilizing a multi gene panel we'll look for the number subjects with positive findings and see how recommendations of care change vs standard of care as recommended by the National Comprehensive Cancer Network (NCCN). Genetic testing and family history may change the practice regarding cancer screening in subjects undergoing kidney transplant evaluation.
Develop a Biorepository	1 year	Create a biorepository based on whole exome sequencing and clinical data for future analysis

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORGirish Mour, MD

Mayo Clinic

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026